# A Study of JNJ-55308942 in the Treatment of Bipolar Depression

> **NCT05328297** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 116 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** JNJ-55308942
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05328297
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-03
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328297, "A Study of JNJ-55308942 in the Treatment of Bipolar Depression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05328297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*